# A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis

> **NCT07684157** · PHASE2 · RECRUITING · sponsor: **Jacobio Pharmaceuticals Co., Ltd.** · enrollment: 32 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** JAB-8263
- **DRUG:** JAB-8263

## Key facts

- **NCT ID:** NCT07684157
- **Lead sponsor:** Jacobio Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-23
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07684157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07684157, "A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07684157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*